Ocular Therapeutix Inc. | Mid-cap | Healthcare
$12.30
1.40%
| Ocular Therapeutix Stock Comparison:
Ocular Therapeutix vs VertexOcular Therapeutix vs RegeneronOcular Therapeutix vs BridgeBio PharmaOcular Therapeutix vs MadrigalOcular Therapeutix vs Blueprint MedicinesOcular Therapeutix vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 13.5M
Gross Profit 11.5M 85.56%
Operating Income -67.6M -502.57%
Net Income -67.8M -503.86%
EPS (Diluted) $-0.39

Balance Sheet Metrics

Total Assets 405.9M
Total Liabilities 140.0M
Shareholders Equity 265.9M
Debt to Equity 0.53

Cash Flow Metrics

Operating Cash Flow -59.7M
Free Cash Flow -56.5M

Revenue & Profitability Trend

Ocular Therapeutix Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i63.7M58.4M51.5M43.5M17.4M
Cost of Goods Sold i5.6M5.3M4.5M4.4M2.1M
Gross Profit i58.1M53.2M47.0M39.1M15.3M
Gross Margin % i91.2%91.0%91.2%89.9%88.0%
Operating Expenses
Research & Development i127.6M61.1M53.5M50.1M28.7M
Selling, General & Administrative i102.2M74.5M72.1M67.1M49.5M
Other Operating Expenses i-----
Total Operating Expenses i229.9M135.5M125.6M117.2M78.2M
Operating Income i-171.8M-82.4M-78.7M-78.0M-62.8M
Operating Margin % i-269.6%-141.0%-152.7%-179.3%-361.1%
Non-Operating Items
Interest Income i20.3M4.0M798.0K33.0K168.0K
Interest Expense i13.6M11.3M7.0M6.7M6.8M
Other Non-Operating Income-28.4M9.0M13.8M78.1M-86.2M
Pre-tax Income i-193.5M-80.7M-71.0M-6.6M-155.6M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-193.5M-80.7M-71.0M-6.6M-155.6M
Net Margin % i-303.7%-138.1%-138.0%-15.1%-894.3%
Key Metrics
EBITDA i-147.7M-75.4M-75.7M-75.6M-59.9M
EPS (Basic) i$-1.22$-1.01$-0.92$-0.09$-2.56
EPS (Diluted) i$-1.22$-1.02$-0.97$-0.98$-2.56
Basic Shares Outstanding i15826516279827362768750357639287060752225
Diluted Shares Outstanding i15826516279827362768750357639287060752225

Income Statement Trend

Ocular Therapeutix Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i392.1M195.8M102.3M164.2M228.1M
Short-term Investments i-----
Accounts Receivable i32.4M26.2M21.3M21.1M12.3M
Inventory i3.0M2.3M2.0M1.2M1.2M
Other Current Assets13.5M7.8M4.0M4.8M4.6M
Total Current Assets i441.0M232.2M129.6M191.3M246.2M
Non-Current Assets
Property, Plant & Equipment i22.7M22.0M20.5M15.9M16.0M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets1.6M1.6M1.8M1.8M1.8M
Total Non-Current Assets i16.9M19.8M19.7M13.6M15.7M
Total Assets i457.9M252.1M149.3M204.9M261.9M
Liabilities
Current Liabilities
Accounts Payable i4.2M4.4M5.1M4.6M2.7M
Short-term Debt i1.9M1.6M1.6M1.6M9.6M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i41.4M34.9M31.4M26.3M26.7M
Non-Current Liabilities
Long-term Debt i73.8M81.8M62.7M57.4M48.8M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities141.0K108.0K93.0K--
Total Non-Current Liabilities i101.2M126.0M82.5M90.6M159.1M
Total Liabilities i142.6M160.9M113.9M116.9M185.8M
Equity
Common Stock i16.0K12.0K8.0K8.0K8.0K
Retained Earnings i-891.1M-697.6M-616.8M-545.8M-539.3M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i315.3M91.1M35.4M88.0M76.1M
Key Metrics
Total Debt i75.8M83.4M64.3M59.0M58.4M
Working Capital i399.6M197.3M98.2M165.0M219.5M

Balance Sheet Composition

Ocular Therapeutix Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-193.5M-80.7M-71.0M-6.6M-155.6M
Depreciation & Amortization i3.8M3.0M2.1M2.4M2.8M
Stock-Based Compensation i33.1M17.8M17.0M15.0M7.5M
Working Capital Changes i-8.2M-4.4M-1.0M-6.5M1.3M
Operating Cash Flow i-161.1M-58.2M-48.1M9.0M-139.6M
Investing Activities
Capital Expenditures i-1.3M-6.1M-3.7M-1.2M-841.0K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-1.3M-6.1M-3.7M-1.2M-841.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i082.5M03.7M3.2M
Debt Repayment i0-28.1M0-4.2M-3.2M
Financing Cash Flow i317.4M166.4M0-720.0K224.7M
Free Cash Flow i-136.0M-76.3M-63.3M-66.7M-54.4M
Net Change in Cash i155.0M102.1M-51.8M7.0M84.2M

Cash Flow Trend

Ocular Therapeutix Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -9.69
Forward P/E -11.90
Price to Book 6.86
Price to Sales 37.28
PEG Ratio -0.19

Profitability Ratios

Profit Margin 91.17%
Operating Margin -502.57%
Return on Equity -63.41%
Return on Assets -31.14%

Financial Health

Current Ratio 10.10
Debt to Equity 25.15
Beta 1.49

Per Share Data

EPS (TTM) $-1.26
Book Value per Share $1.77
Revenue per Share $0.34

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ocul2.1B-9.696.86-63.41%91.17%25.15
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.